Mitochondrial F1Fo ATP synthase (Complex V)

Mitochondrial F1Fo ATP synthase, also known as Complex V, is a multi-subunit enzyme complex located in the inner mitochondrial membrane that plays a critical role in cellular energy production [1.1.1, 1.1.2]. It functions as a rotary molecular motor, utilizing the electrochemical proton gradient generated by the electron transport chain to synthesize ATP from ADP and inorganic phosphate [1.1.3, 1.5.2]. Beyond its primary role in oxidative phosphorylation, the complex is involved in maintaining mitochondrial cristae structure and regulating the mitochondrial permeability transition pore (mPTP), a key factor in cell death pathways [1.1.1, 1.2.1]. Dysregulation or mutations in its subunits are linked to severe mitochondrial disorders such as Leigh syndrome and NARP, as well as neurodegenerative and cardiovascular diseases [1.1.2, 1.4.1]. Pharmacological targeting of the enzyme includes inhibitors like oligomycin and experimental agents like Bz-423, which can modulate ATP production or induce apoptosis in specific cell types [1.3.2, 1.3.3]. While primarily targeted for its role in bioenergetics, its involvement in the mPTP makes it an attractive target for cardioprotection and cancer therapy [1.2.1, 1.2.5].

Other names

ATP synthaseComplex VF-type ATPaseMitochondrial ATP synthaseH+-transporting ATP synthaseF1Fo-ATPaseATP phosphohydrolase (H+-transporting)

Drugs targeting mitochondrial F1Fo ATP synthase primarily act by inhibiting the rotary mechanism or blocking the proton channel (Fo sector), thereby preventing ATP synthesis or hydrolysis [1.2.5, 1.3.2]. Some agents, like Bz-423, bind to specific subunits such as OSCP to induce conformational changes that trigger ROS production and apoptosis [1.3.2]. Others selectively inhibit the hydrolase activity to preserve ATP levels during ischemic conditions [1.2.5].